RECRUITINGOBSERVATIONAL

A Clinical Study of Hyperthyroidism in Children

A Retrospective and Prospective Observational Study of Hyperthyroidism in Children

About This Trial

This study intends to conduct a retrospective and prospective study on children with hyperthyroidism, and it is a non-intervention study to collect information on diagnosis and treatment and long-term follow-up of children with hyperthyroidism. To investigate the clinical characteristics, treatment effect, side effects and remission of hyperthyroidism in children, to analyze the predictive factors for the effect of antithyroid drug treatment, remission and recurrence after drug withdrawal, and to explore the risk factors related to the occurrence of antithyroid drug-related adverse reactions.

Who May Be Eligible (Plain English)

Who May Qualify: 1. Age ≤14 years old 2. Initial diagnosis of hyperthyroidism Who Should NOT Join This Trial: 1. Hyperthyroidism had been treated with medication in other hospitals, 2. History of autoimmune hepatitis, viral hepatitis, hematological diseases, bone marrow or liver transplantation, 3. Patients with incomplete clinical data Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: 1. Age ≤14 years old 2. Initial diagnosis of hyperthyroidism Exclusion Criteria: 1. Hyperthyroidism had been treated with medication in other hospitals, 2. History of autoimmune hepatitis, viral hepatitis, hematological diseases, bone marrow or liver transplantation, 3. Patients with incomplete clinical data

Treatments Being Tested

DRUG

Methimazole(MMI)

The initial dose of methimazole was 0.2-0.8 mg/(kg▪d). This dose was subsequently reduced by 25% to 50% and adjusted to maintain euthyroidism, based on the results of serum thyroid hormone testing during follow-up.

Locations (1)

Shengjing Hospital of China Medical University

Shenyang, Liaoning, China